A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511426-31-00

Acronym

IRL757C001

Enrollment

Registered

2024-05-03

Start date

2024-05-16

Completion date

2025-02-07

Last updated

2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apathy in neurodegenerative disorders

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026